<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="93">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379297</url>
  </required_header>
  <id_info>
    <org_study_id>CNER 202004/01</org_study_id>
    <secondary_id>831x6ce0d</secondary_id>
    <secondary_id>FNR/CON-VINCE</secondary_id>
    <nct_id>NCT04379297</nct_id>
  </id_info>
  <brief_title>COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)</brief_title>
  <acronym>CON-VINCE</acronym>
  <official_title>COvid-19 National Survey for Assessing VIral Spread by Nonaffected CarriErs (CON-VINCE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luxembourg Institute of Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Luxembourg National Research Funds</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Luxembourg/ Luxembourg Centre for Systems Biomedicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier du Luxembourg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>TNS-Ilres</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoires Réunis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>BioneXt Lab</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ketterthill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Laboratoire National de santé</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Luxembourg Institute of Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CON-VINCE (COvid-19 National survey for assessing VIral spread by Non-affected CarriErs) is a
      national, monocentric, and longitudinal study aiming to evaluate the spread dynamics of the
      COVID-19 disease within the Luxembourgish population. Participants who are clinically
      asymptomatic or present with only mild symptoms will be followed up longitudinally, regularly
      tested for SARS-CoV-2 by RT-PCR, antibody status, and subjected to an epidemiological,
      clinical and biological phenotyping to better understand the nature, dynamics of infectivity
      and spread of the virus in the population. CON-VINCE will also track the psychological and
      socio-economic impact of long-term containment measures on the general population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To capture the dynamics and impact of the virus spread in the Luxembourgish population, data
      and sample collection is done every two weeks for two months (4 times in total) with a final
      follow-up one year after the participant's inclusion in the study. Participants complete
      questionnaires before each sample collection. The baseline questionnaire captures demographic
      data, medical history, behavioral and psychological data, and socio-economic status.
      Participants provided information on medical history, history of allergies, smoking, and
      chronic medication taken regularly. COVID-19-related data and environmental conditions of the
      household were obtained.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence and dynamics of the SARS-COV 2 infection in Luxemburg</measure>
    <time_frame>04.2020-05.2021</time_frame>
    <description>Evaluation of the prevalence by RT-PCR and serology testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collection of samples for research</measure>
    <time_frame>04.2020-05.2021</time_frame>
    <description>Samples will be analysed and stored for future research</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psycho-social evaluation</measure>
    <time_frame>04.2020-05.2021</time_frame>
    <description>Psychological and socio- economic impact of long-term containment measures on the general population</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>COVID19</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Naso-pharyngeal swab, Oro-pharyngeal swab, Blood, sputum,Stool
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Representative panel of the Luxembourgish population
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects aged 18 and older of both genders, with a full capacity of consent.

          -  SARS-CoV-2-positive individuals with an asymptomatic or oligosymptomatic infection
             (mild or oligosymptomatic disease course is defined as absence of fever and
             respiratory distress or cough not attributable to other known chronic disease).

          -  OR SARS-CoV-2-negative individuals at the time of inclusion.

          -  OR post-infectious SARS-CoV-2-negative individuals with acquired immunity to
             SARS-CoV-2 and a mild disease course.

        Exclusion Criteria:

          -  Evolution of the COVID-19 disease requiring a hospital admission before inclusion in
             the study

          -  Presence of fever and respiratory distress/cough at the time of inclusion not
             attributable to other known chronic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rejko Krüger, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Luxembourg Institute of Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Luxembourg Institute of Health</name>
      <address>
        <city>Strassen</city>
        <zip>1445</zip>
        <country>Luxembourg</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Luxembourg</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>COVID</keyword>
  <keyword>Prevalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

